@uoflenvirome.bsky.social @uoflmedicine.bsky.social @stevenpjones.bsky.social #musclesky #cardiosky #HFrEF #heartfailure #skeletalmuscle #cardiology
1
2
0
0
Hashtag
#HFrEF
Advertisement · 728 × 90
JAMA Cardiology presents an editorial, "Prioritizing Time from Diagnosis to Quadruple Therapy in Heart Failure Care," by Neil M. Kalwani text@1, Jessica R. Golbus text@2, and Stephen J. Greene text@3. Published online April 1, 2026.
💬 Editorial: Among patients with #HFrEF in the Veterans Health Administration, fewer than 1 in 6 achieved quadruple therapy and the median time to initiation exceeded 6 months.
ja.ma/41Ef3Vj
1
1
0
0
FUND-HF pilot shows feasible post-discharge financial support for vulnerable #HFrEF patients with high #SDOH burden and poor HRQOL. Early efficacy, safety, and design insights support a larger multicenter trial. https://bit.ly/4bIWRzK
#ACC26 #JACCAdvances #QoL #CardioSky
0
0
0
0
Figure 2 shows temporal trends in outcomes for heart failure patients with reduced ejection fraction after quadruple therapy. Graph A: 30-day follow-up; Graph B: 12-month. Both graphs compare cumulative incidence % between July-Sept text@1 and Oct-Dec text@2.
In US practice, older adults hospitalized for #HFrEF and prescribed quadruple therapy still face 1 in 5 risk of death and 1 in 4 risk of heart failure rehospitalization at 1 year, with high associated health care costs.
ja.ma/4cTH9mg
1
2
0
0
This study builds a bedside #nomogram including NOAF, age, NYHA class, sodium, platelets, and #GDMT to predict post-CRT mortality in #HFrEF, showing high accuracy & enabling personalized risk stratification, follow-up, & therapy optimization to improve outcomes.
#OpenAccess: tinyurl.com/2c6u2rk2
0
0
0
0
Figure 2 shows temporal trends in clinical outcomes for heart failure patients with reduced ejection fraction. Graph A: 30-day follow-up, Graph B: 12-month follow-up. Bars compare cumulative incidence in July 2021-Sept 2022 to Oct 2022-Dec 2023.
Among older patients hospitalized for #HFrEF, prescription of quadruple medical therapy at discharge was associated w/ a 1-year mortality of 19% and heart failure rehospitalization rate of 26%, w/ median health care costs of nearly $28,000 per patient.
ja.ma/4akLpJT
0
0
0
0
Managing HF Across the Spectrum: This interactive online course offers practical tools to assess risk, classify HF phenotypes, & apply GDMT through an interprofessional care lens. Learn how to tackle pivotal issues in #HFrEF, & more. 👇
🔖 https://bit.ly/3O8JvDp
#ACCEd #CardioSky #MedSky
3
1
0
0
Figure shows temporal trends in clinical outcomes for heart failure patients with reduced ejection fraction. Two bar graphs compare cumulative incidence (%) at 30-day & 12-month follow-ups for all-cause mortality, HF hospitalization, & combined outcomes.
Among older patients hospitalized for #HFrEF, prescription of quadruple medical therapy at discharge was associated with a 1-year mortality of 19% and heart failure rehospitalization rate of 26%, with median health care costs of nearly $28,000 per patient.
ja.ma/4t1I8ql
0
0
0
0
Niveles elevados de LDH se asocian con un riesgo elevado de variables clínicas en la insuficiencia cardíaca con fracción de eyección reducida #HFrEF. #LDH www.jacc.org/doi/10.1016/...
0
0
0
0
JAMA study: treatments for heart failure(HF) effective for HF with reduced ejection fraction due to Chagas disease? 922 patients randomized. Sacubitril/valsartan: 23.8% death from cardiovascular causes. Enalapril: 25.4%. NT-proBNP change: -30.6% vs -5.5%.
RCT: In patients with #Chagas-related #HFrEF, sacubitril/valsartan did not reduce rates of cardiovascular death or heart failure hospitalization compared with enalapril.
ja.ma/4aNRXBs
2
2
0
0
The VICTOR study results complement those of the VICTORIA by extending the evidence base for vericiguat in a contemporary lower-risk, well-treated ambulatory #HFrEF population.
Explore more insights from the VICTOR trial ➡️ https://bit.ly/4blPC0O #HeartFailure
0
1
0
0
JAMA study: Sacubitril/valsartan vs. enalapril for heart failure due to Chagas disease. 922 patients randomized. Findings: Sacubitril/valsartan showed a greater reduction in NT-proBNP compared to enalapril. No significant difference in death/hospitalization.
RCT: In patients with #Chagas-related #HFrEF, sacubitril/valsartan did not reduce rates of cardiovascular death or heart failure hospitalization compared with enalapril.
ja.ma/4aex1mK
3
1
0
0
How is your team addressing chronic disease education? Share your strategies! 👇
8/7
#MoreThanAJournal #howwehospitalist #HeartFailure #PatientEducation #HospitalMedicine #GDMT #HFpEF #HFrEF #MedTwitter
0
0
0
0
Heart failure with reduced ejection fraction.
www.thelancet.com/journals/lan...
@thelancet.com
#CardioSky #HFrEF #HeartFailure
0
2
0
0
📢 POLY-HF: Daily Polypill Boosts Heart Function, QOL, and Cuts Hospitalizations in Underserved Patients With #HFrEF
Read more: https://bit.ly/4hV9byv
#AHA25 #HeartFailure #CardioSky #MedSky
4
2
1
1
ACC CardiaCast: In this episode, Drs. @mkittlesonmd.bsky.social & Estefania Oliveros Soles discuss the biggest challenges in #HFrEF and #HFpEF, focusing on hyperkalemia (uncommon) and hypokalemia (associated with higher mortality).
Tune in here ➡️ https://bit.ly/46Tt8lk #HeartFailure #CardioSky
1
3
0
0
Explore current treatments for primary central nervous system lymphoma, including those involving high-dose #methotrexate, and their implications for patients with #HFrEF.
👉https://buff.ly/hHicXoQ
#NeuroSky #PCNSL
0
0
0
0
Vericiguat reduce riesgo de hospitalización por insuficiencia cardíaca y muerte por causas CV en pac c/insuficiencia cardíaca c/fracción de eyección reducida, independientemente de la gravedad, incluyendo los q reciben terapia médica según guías #vericiguat #HFrEF www.thelancet.com/journals/lan...
0
0
0
0
En pacientes con insuficiencia cardíaca y fracción de eyección reducida que reciben terapia médica según las guías, el tratamiento con digitoxina reduce el riesgo de muerte por cualquier causa o ingreso por empeoramiento de la insuficiencia cardíaca #digitoxin #HFrEF www.nejm.org/doi/full/10....
0
0
0
0
In #HFrEF, quadruple therapy (ARNi, β-blockers, MRA, #SGLT2i) improves survival. Adding #vericiguat may offer a modest ~0.7-year gain, though findings are exploratory, as they are derived from a secondary endpoint of a single trial https://bit.ly/4mE83Rp
#JACC #ESCCongress #WCCardio
6
7
0
0
When to downtitrate/stop #GDMT in #HFrEF? Prof #BiykemBozkurt 🫀
📍Recovered: individualized, may consider de-escalation
📍Improving: continue/optimize
📍Persistent: escalate, close FU/referral
📍Refractory: ⬇️doses/advanced tx
⚠️No solid data for routine withdrawal
#ESCCongress @escardio.bsky.social
5
2
2
1
🔥 long awaited data on digitoxin💊 in chronic #HFrEF
✔️ significant reduction in death or first hospital admission for worsening heart failure
✔️ treatment with digitoxin was safe
nejm.org/doi/full/10.10…
➡️ more data on digoxin to follow next year #DECISIONtrial @escardio.bsky.social
4
1
0
0
🚨 #HFpEF ≠ #HFrEF! Turns out, the #immunesystem knows the difference. We profiled #immunecells in HFpEF patients (scRNA-seq) & mice-showing conserved inflammatory programs & the therapeutic potential of #NO₂-OA. 👉 doi.org/10.1161/CIRC...
2
0
0
0
#SOLOISTWHF is an example of sheermarketing. Enlist a highly diverse cohort of 79% HFrEF and 21% #HfrEF then market the results as positive for HfpEF. A closer look at the CI reveals an imprecise underpowered & completely useless trial. Pure marketing.
1
0
0
0
0
0
0
0
Read our latest issue, Drugs for Chronic Heart Failure: bit.ly/44E8FjQ
The Comparison Chart: Some Drugs for HFrEF is freely accessible.
#Heartfailure #FOAMed #HFrEF #HFpEF
0
0
0
0
【診断後早期のGDMT開始 [可能例】でHFrEFの転帰改善/ ESC HF
デンマークHFレジストリ、HFrEF 46,816例観察：
・診断４週間以内のガイドライン推奨薬「3~4」剤「開始」で「非開
始」に比べ、１年間死亡の補正後HRは0.65 [95CI：0.55-0.78]、３
年間なら0.67 [0.59-0.76]。
・一方、「1~2」剤開始でも0.73 [95%CI：0.61-0.86]と0.75 [0.66-
0.86]。
・CV死亡も同様。
x.gd/OA954
#HFrEF #GDMT
0
0
0
0
🚦Latest @medscape.com Primary Care #hack is live!
🔥Paired #hacks covering the diagnosis & management of #HFrEF & #HFpEF in primary care
PDF download link in comments 👇🏾
@pharmrj.pharmsky.app @goggledocs.bsky.social @hpillminster.pharmsky.app
5
2
2
2
New study in #JACCHF on growth hormone (GH) replacement in patients with GH deficiency + #HFrEF
🔸 Improved exercise capacity + #QoL in GH replacement vs controls
🔸 Impetus here to screen for GH more, consider in those with residual symptoms despite #GDMT
📎: www.jacc.org/doi/10.1016/... #CardioSky
7
4
0
0
Awesome talk from @mkittlesonmd.bsky.social on #HF in women from #GDMT to #VAD and #transplant #HFpEF #HFrEF
@womensheart.bsky.social
#CardioSky
3
3
0
0